子宮内膜症：市場分析及び予測（～2017）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 7
1.1 List of Tables 11
1.2 List of Figures 13
2 Introduction 14
2.1 Catalyst 14
2.2 Related Reports 14
3 Disease Overview 15
3.1 Etiology and Pathophysiology 15
3.2 Etiology 17
3.3 Pathophysiology 17
3.4 Clinical Prognosis 20
3.5 Quality of Life 20
3.6 Symptoms and Diagnosis 21
4 Epidemiology 22
4.1 Risk Factors and Comorbidities 22
4.1.1 Family history is a strong predictor for the risk of endometriosis 22
4.1.2 Late age at menarche protects women from developing endometriosis. 23
4.1.3 Higher parity decreases the risk for endometriosis 24
4.2 Global Trends 26
4.2.1 US 27
4.2.2 5EU 27
4.2.3 Forecast Methodology 28
4.2.4 Sources Used 29
4.2.5 Sources Not Used 32
4.2.6 Forecast Assumptions and Methods 32
4.3 Epidemiological Forecast for Endometriosis (2012-2022) 35
4.3.1 Diagnosed Prevalent Cases of Endometriosis 35
4.3.2 Age-Specific Prevalent Cases of Endometriosis 36
4.3.3 Age-Standardized Diagnosed Prevalence of Endometriosis 38
4.3.4 Diagnosed Prevalent Cases of Endometriosis by Stage 39
4.4 Discussion 41
4.4.1 Epidemiological Forecast Insight 41
4.4.2 Limitations of the Analysis 42
4.4.3 Strengths of the Analysis 43
5 Current Treatment Options 45
5.1 Overview 45
5.2 Product Profiles – Major Brands 48
5.2.1 Zoladex (goserelin acetate) 48
5.2.2 Lupron (leuprolide acetate depot) 51
5.2.3 Synarel (nafarelin nasal spray) 53
5.2.4 Visanne (dienogest) 56
5.2.5 Depo-SubQ Provera 104 (medroxyprogesterone injection) 59
5.2.6 Danazol (Danocrine) 61
5.2.7 Off-Label Treatment: Combined Oral Contraceptives, Progestins, and NSAIDs 63
6 Unmet Needs Assessment and Opportunity Analysis 67
6.1 Overview 67
6.2 Unmet Needs Analysis 68
6.2.1 Unmet Need: Non-Invasive Diagnostics 68
6.2.2 Unmet Need: Non-Hormonal Therapies 69
6.2.3 Unmet Need: Better Pain Management 69
6.2.4 Unmet Need: Better Understanding of the Disease Pathology to Prevent Recurrence 70
6.2.5 Unmet Need: Identification of Biomarkers 71
6.2.6 Unmet Need: Transparency in Clinical Trials 71
6.3 Opportunity Analysis 72
6.3.1 Opportunity: Biomarkers Identification 72
6.3.2 Opportunity: Treatment Options for Adolescents 73
6.3.3 Opportunity: Drugs Targeting Pain Pathways 73
6.3.4 Opportunity: Novel Targets 74
6.3.5 Opportunity: Efficacious Treatments Suitable for Long-Term Use 74
6.4 Research and Development Strategies 75
6.4.1 Overview 75
6.4.2 The Race for the Development of GnRH Antagonists 76
6.4.3 Alliances and In-Licensing Strategies 76
6.4.4 Maximizing Return-on-Investment by Targeting Secondary indications 77
6.5 Clinical Trial Design 78
6.5.1 Overview 78
6.5.2 Defining Efficacy in Endometriosis Clinical Trials 78
6.5.3 Future Trends in Endometriosis Clinical Trial Design 83
7 Pipeline Assessment 84
7.1 Overview 84
7.2 Promising Drugs in Development 85
7.2.1 Elagolix (ABT-602) 86
7.2.2 Relugolix (TAK-385) 90
7.2.3 ASP-1707 92
7.3 Innovative Early-Stage Approaches 94
7.3.1 Overview 94
7.3.2 Anti-Inflammatory Approaches 96
7.3.3 Cellular Adhesion 97
7.3.4 Angiogenesis Endometriotic Implants 97
7.3.5 Selective Progesterone Receptor Modulators 98
7.3.6 Aromatase Inhibitors 99
8 Pipeline Valuation Analysis 100
8.1 Overview 100
8.2 Clinical Benchmarking of Key Pipeline Drugs 100
8.3 Commercial Benchmarking of Key Pipeline Drugs 104
8.4 Competitive Assessment 105
8.5 Top-Line, Five-Year Forecasts 106
8.5.1 Overview 106
8.5.2 US 109
8.5.3 5EU 110
9 Appendix 112
9.1 Bibliography 112
9.2 Abbreviations 123
9.3 Methodology 126
9.4 Forecasting Methodology 126
9.4.1 Diagnosed Endometriosis Patients 127
9.4.2 Percent Drug Treated Patients 128
9.4.3 Drugs Included in Each Therapeutic Class 129
9.4.4 Launch and Patent Expiry Dates 129
9.4.5 General Pricing Assumptions 130
9.4.6 Individual Drug Assumptions 130
9.4.7 Generic Erosion 133
9.4.8 Pricing of Pipeline Agents 133
9.5 Physicians and Specialists Included in This Study 134
9.6 About the Authors 135
9.6.1 Author 135
9.6.2 Epidemiologist 135
9.6.3 Global Director of Epidemiology and Health Policy 136
9.6.4 Global Head of Healthcare 136
9.7 About GlobalData 137
9.8 Disclaimer 137